BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 27, 2026
View BioWorld MedTech
Home » Shuren says IMDRF still out on single review; FDA moving ahead
To read the full story, subscribe or sign in.

Shuren says IMDRF still out on single review; FDA moving ahead

Sep. 28, 2018
By Mark McCarty
PHILADELPHIA – The FDA town hall at the various med-tech meetings usually offers at least an update on recent developments, and Jeff Shuren advised attendees at the FDA town hall here at the MedTech Conference that the International Medical Device Regulators Forum (IMDRF) is still not quite sold on the Medical Device Single Review Program (MDSRP). Still, Shuren said, the FDA's device center is "already moving unilaterally to make some changes to get us there" on MDSRP.
Medical technology

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 26, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Microscopy of a cross-section of mouse skin containing melanoma tumors

    Researchers identify innate immune barrier against melanoma

    BioWorld
    Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
  • Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

    BioWorld Science
    Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
  • Green and red bispecific antibodies

    Biotle’s FcRn inhibitor BTL-203 cleared for clinic in China

    BioWorld Science
    Biotle has received a clinical trial notice from China’s National Medical Products Administration (NMPA) for its IND application for BTL-203, the company’s...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing